Related Experiment Videos
COPD and Osteoporosis: Epidemiology, Pathophysiology, Clinical Impact, and Management Strategies: A Narrative Review
Rohit Kondameda1, Siri Kolliputi2, Narasaiah Kolliputi3
1College of Natural Sciences and Mathematics, The University of Texas at Dallas, Richardson, TX.
Background:
Chronic obstructive pulmonary disease (COPD) and osteoporosis are highly prevalent chronic conditions that frequently co-occur, yet their comorbid relationship remains systematically underrecognized in clinical practice. Approximately 38% of COPD patients have confirmed osteoporosis, yet fewer than 20% receive bone-protective pharmacotherapy.
Objective:
To synthesize current evidence on the epidemiology, shared pathophysiological mechanisms, clinical consequences, and integrated management strategies for COPD-associated osteoporosis.
Methods:
A narrative review was conducted through systematic searching of PubMed and MEDLINE (through December 2024) using the terms 'COPD,' 'osteoporosis,' 'bone mineral density,' 'fracture risk,' and 'corticosteroids.' Peer-reviewed original research, systematic reviews, meta-analyses, and clinical guidelines were included. Non-peer-reviewed sources were excluded.
Results:
Shared mechanisms underlying COPD-associated osteoporosis include chronic systemic inflammation (elevated IL-6, TNF-α), corticosteroid-induced bone loss, sarcopenia, vitamin D deficiency, and overlapping risk factors including smoking, advanced age, and low BMI. Osteoporotic fractures, particularly vertebral and hip, independently increase all-cause mortality, worsen pulmonary mechanics, accelerate functional decline, and generate direct healthcare costs exceeding $17 billion annually in the United States (a general US osteoporotic-fracture cost estimate, not specific to COPD). Despite this burden, screening rates are low and treatment is substantially underutilized.
Conclusions:
Osteoporosis in COPD represents a modifiable comorbidity with major and measurable clinical impact. Proactive DXA-based screening, individualized pharmacotherapy with bisphosphonates or denosumab, pulmonary rehabilitation, and multidisciplinary coordinated care are evidence-supported strategies that remain underimplemented. Updating COPD clinical guidelines to mandate systematic bone health assessment is an urgent priority.
Related Concept Videos
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: